However, there was no significant difference in the incidence of carcinoma in situ (CIS) (33.3% in Orp3-KO and 30.8% in control group), suggesting that Orp3 impaired the progression of tumors towards invasive carcinoma. The gene discussed is OSBPL3; the disease is in situ carcinoma.